Diabetic ketoacidosis shortly after COVID-19 vaccination in a non-small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report.

Makiguchi, Tomonori; Fukushima, Takashi; Tanaka, Hisashi; Taima, Kageaki; Takayasu, Shinobu; Tasaka, Sadatomo

Makiguchi, Tomonori; Fukushima, Takashi; Tanaka, Hisashi; Taima, Kageaki; Takayasu, Shinobu; Tasaka, Sadatomo.

Makiguchi T; Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Fukushima T; Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Tanaka H; Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Taima K; Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Takayasu S; Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Tasaka S; Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Thorac Cancer ; 13(8): 1220-1223, 2022 04.

Article in English | MEDLINE | ID: covidwho-1685174

ABSTRACT

ABSTRACT

We describe a case of diabetic ketoacidosis (DKA) shortly after the SARS-CoV-2 (COVID-19) vaccination in a 65-year-old woman with non-small-cell lung cancer under a combination treatment of programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors. She had no history of diabetic mellitus. A few days after the second shot of COVID-19 vaccination, she developed DKA. We speculate that the immune-related adverse event and immunogenicity of vaccination synergistically induced DKA.

Subject(s)

COVID-19; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus; Diabetic Ketoacidosis; Lung Neoplasms; Aged; COVID-19 Vaccines/adverse effects; CTLA-4 Antigen/therapeutic use; Carcinoma, Non-Small-Cell Lung/complications; Carcinoma, Non-Small-Cell Lung/drug therapy; Diabetic Ketoacidosis/chemically induced; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms/complications; Lung Neoplasms/drug therapy; Programmed Cell Death 1 Receptor/therapeutic use; SARS-CoV-2; Vaccination/adverse effects

Keywords

COVID-19 vaccination; diabetic ketoacidosis; immune checkpoint inhibitor; immune-related adverse event

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetic Ketoacidosis / Carcinoma, Non-Small-Cell Lung / Diabetes Mellitus / COVID-19 / Lung Neoplasms Type of study: Case report / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Aged / Female / Humans Language: English Journal: Thorac Cancer Year: 2022 Document Type: Article Affiliation country: 1759-7714.14352

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google